PETER IGE: Open Payments
NPI 1164060943 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,318 in 53 payments from 10 companies in 2025. Trend: 2023 $1,193 · 2024 $1,578 · 2025 $1,318
Food & beverage: $1,318
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 25 | $474 |
| Teva Pharmaceuticals USA, Inc. | 5 | $324 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $205 |
| Alkermes, Inc. | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| ABBVIE INC. | 3 | $47 |
| Lundbeck LLC | 2 | $43 |
| Almatica Pharma LLC | 1 | $31 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $22 |
Products named: INGREZZA, UZEDY, CAPLYTA, REXULTI, ARISTADA, FANAPT, VRAYLAR, LOREEV XR.
Industry payments across MD — which companies pay providers there.
